Aseptic manufacturing is a process where great care is taken to ensure that the final product is free from any contamination. It requires precision and consistency to create high-quality products. Robots are well-suited for this task as they can perform operations with high accuracy and repeatability, which are crucial for aseptic processing. As robotics technology continues to advance, many pharmaceutical equipment manufacturers are working on developing robotic isolator technology.
For example, Vanrx Pharmasystems Inc. has developed the SA25 Aseptic Filling Workcell, which is a robotic isolator that eliminates the need for gloves. Robots in this system handle all the materials, filling, and closing activities within a completely closed isolator. This advanced technology has been widely adopted in the pharmaceutical industry, contributing to market growth. In fact, in May 2018, Fujifilm diosynth expanded its fill/finish services for gene therapies and viral vaccines using Vanrx's SA25 Aseptic Filing Workcell.
Furthermore, some companies are working on developing robotics that are compatible with pharmaceutical isolators. Staubli Robotics, a robot manufacturing company, has developed the TX series Stericlean and 6-axis robot arms that can work seamlessly with pharmaceutical isolators. This compatibility ensures that the robots can perform their tasks effectively within the isolator environment.
These technological advancements in isolation technology create favorable conditions for market players to expand their product offerings and ultimately contribute to the growth of the market. By incorporating robotics into pharmaceutical isolators, manufacturers can improve the efficiency, accuracy, and reliability of aseptic manufacturing processes. This, in turn, leads to better quality products and increased productivity in the pharmaceutical industry.
As the demand for aseptic manufacturing continues to rise, the market for robotic isolators will likely experience significant growth. The use of robots in this field not only improves the quality of the final products but also enhances worker safety by reducing their exposure to potentially harmful substances. Moreover, the automation provided by robots enables faster production times and reduces the risk of human error.
In conclusion, the integration of robotics into pharmaceutical isolators is a technological advancement that is driving market growth. Robots offer precise and repeatable operations necessary for aseptic processing, ensuring the production of high-quality pharmaceutical products. As more companies adopt these advanced robotic isolators and develop compatible robotics, the market will continue to expand, benefiting both manufacturers and consumers in the pharmaceutical industry.
Report Attribute/Metric | Details |
---|---|
Segment Outlook | Pressure,Application and End-User |
Regional Market Summary
Global Open System Isolator Market Share, by Region, 2017 (%)
Source: MRFR Analysis
The Americas are likely to hold the first place in the global open system isolator market due to the presence of well-established pharmaceutical industry, technological advancement in the region and adoption of high technology, and presence of strict government policies in the region. According to the International Trade Administration (ITA), in 2015, the biopharmaceutical industry in the US spent more than USD 75 billion on research and development activities, which is half of the global biopharma R&D spending.
The European market is expected to be the second-largest open system isolator global market. The market growth in this region is the result of an increasing number of research and development activities in the region, growing concern about the safety of the drug and increasing inspections by regulatory authorities. The contribution of Germany and France is noticeable in the growth of European open system isolator market. For instance, according to the report published by Germany Trade & Invest in 2017, the German pharmaceutical market was worth USD 45 billion (2017) and is the largest market in Europe and holds fourth place in the global pharmaceutical industry.
Asia-Pacific is expected to be the fastest-growing open system isolator global market during the forecast period owing to the presence of a strong generics market and increasing export of generic drugs from the countries like China and India. For instance, according to the Indian Brand Equity Foundation (Ministry of Commerce & Industry, Government of India), Indian companies exported pharmaceuticals worth USD 17.27 billion during 2017 to 2018 which is expected to grow at a rate of 30% to reach USD 20 billion by 2020.
The market in the Middle East & Africa is expected to account for the smallest share of the open system isolator global market due to poor infrastructure and slow development of the healthcare sector.
Key Players
Some of the key players in the open system isolator are Gelman Singapore Pte Ltd, COMECER S.p.A. cf. p.iva, IsoTech Design, LAF Technologies Pty Ltd, Fedegari Autoclavi S.p.A, Hosokawa Micron Ltd, Robert Bosch GmbH, MBRAUN, Schematic Engineering Industries, NuAire Inc, VanRx Pharmasystems Inc, Azbil Telstar, Getinge AB, Skan AG, Chamunda Pharma Machinery Pvt. Ltd., and GERMFREE
Global Open System Isolator Market, by Pressure
Global Open System Isolator Market, by Application
Global Open System Isolator Market, by End-User
Global Open System Isolator Market, by Region
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)